Clinical Accelerator, a full-service, medical device focused contract research organization, is pleased to announce a partnership with Airiver Medical, to evaluate the safety and efficacy of Airiver’s pulmonary Drug-Coated Balloon in the FIM treatment of benign Central Airway Stenosis.

Central airway obstruction leads to a significant level of morbidity due to dyspnea and greatly reduced quality of life. Airiver’s DCB is hypothesised to improve patient outcome through the endoscopic treatment. Airiver’s balloon is coated with the Paclitaxel drug, similar to the Urotronic Optilume drug-coated balloon for urinary strictures which was recently approved by FDA.

Patients will be followed up for a year and we are very excited to take responsibility for the implementation and management of this study at our partner institution.

About Clinical Accelerator

Clinical Accelerator is an independent clinical trial management organisation operating principally in Central and Eastern Europe. The organisation offers a broad range of clinical trial services together with dedicated patient enrolment support to worldwide clients in the pharmaceutical, biotechnological and medical device industries. Clinical Accelerator’s model of operation is designed to achieve significant cost savings for its clients and to guarantee compact timelines for patient enrolment with a firm focus on the quality of clinical trial data.